Sunesis Pharmaceuticals


$33.2m market cap

$0.55 last close

Sunesis Pharmaceuticals is a pharmaceutical company focused on oncology. The company has developed vecabrutinib, a BTK inhibitor for CLL for Imbruvica refractory patients currently in Phase I/II.

Investment summary

Sunesis is a pharmaceutical company developing small molecule oncology drugs. Its lead programme is vecabrutinib, a novel non-covalent, oral BTK inhibitor that may work in Imbruvica relapsed and refractory patients. Data from a Phase Ia study in healthy volunteers was recently presented and indicated an attractive PK/PD profile with twice-a-day dosing. The programme is in a dose escalation Phase Ib/II trial. It has also developed TAK-580 with partner Takeda, and the preclinical PDK1 inhibitor SNS-510.

Y/E Dec
Revenue (US$m)
PBT (US$m)
EPS (c)
P/E (x)
P/CF (x)
2016A 2.5 (36.3) (38.0) (242.37) N/A N/A
2017A 0.7 (34.4) (35.5) (144.63) N/A N/A
2018E 0.2 (27.5) (28.3) (79.53) N/A N/A
2019E 0.0 (30.4) (31.1) (48.97) N/A N/A
Last updated on 20/02/2019
Industry outlook

Sunesis is an oncology company with an early stage asset with a validated target targeting patients that are in B-cell malignancies.

Last updated on 20/02/2019
Share price graph
Balance sheet
Forecast net cash (US$m) 5.8
Forecast gearing ratio (%) N/A
Price performance
Actual 16.5 (50.5) (91.4)
Relative* 11.8 (53.0) (91.6)
52-week high/low US$7.4/US$0.2
*% relative to local index
Key management
William Quinn Chief Financial Officer and Senior Vice Presi

Content on Sunesis Pharmaceuticals